Literature DB >> 26070654

Lymphoma-associated dysimmune polyneuropathies.

Joerg-Patrick Stübgen1.   

Abstract

Lymphoma consists of a variety of malignancies of lymphocyte origin. A spectrum of clinical peripheral neuropathy syndromes with different disease mechanisms occurs in about 5% of lymphoma patients. There exists a complex inter-relationship between lymphoproliferative malignancies and autoimmunity. An imbalance in the regulation of the immune system presumably underlies various immune-mediated neuropathies in patients with lymphoma. This article reviews lymphoma and more-or-less well-defined dysimmune neuropathy subgroups that are caused by humoral and/or cell-mediated immune disease mechanisms directed against known or undetermined peripheral nerve antigens.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoantibodies; Autoimmunity; Immune-mediated-inflammation–demyelination; Lymphoma; Polyneuropathy

Mesh:

Year:  2015        PMID: 26070654     DOI: 10.1016/j.jns.2015.06.003

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  4 in total

Review 1.  Chemotherapy-induced peripheral neuropathy: A current review.

Authors:  Nathan P Staff; Anna Grisold; Wolfgang Grisold; Anthony J Windebank
Journal:  Ann Neurol       Date:  2017-06-05       Impact factor: 10.422

Review 2.  Peripheral Nervous System Involvement in Lymphoproliferative Disorders.

Authors:  Mario Sabatelli; Luca Laurenti; Marco Luigetti
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-09-01       Impact factor: 2.576

3.  Diffuse large B-cell lymphoma involving peripheral nervous system with IgM antibodies against GM1 and GD1b: A case report.

Authors:  Zhaocai Jiang; Weina Ju; Shen Luo; Yu Yang
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

4.  Guillain-Barré syndrome and COVID-19: association or coincidence.

Authors:  Aislinn Gale; Suganya Sabaretnam; Asher Lewinsohn
Journal:  BMJ Case Rep       Date:  2020-11-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.